China Ups Penalties For Quality Violators Under Tougher Regulation
This article was originally published in PharmAsia News
The China FDA has officially released a new regulation governing unannounced inspections for drug and device manufacturers, ranging from production to distribution to product use, with many expecting more frequent inspections and stricter enforcement. Although traditional medicine manufacturers are the main target for now, the scope of focus could be expanded.
You may also be interested in...
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.
Amid a sweeping National Security Law passage, many biotech and healthcare firms from China opt for a Hong Kong initial public offering in the meanwhile appetite for a US listing wanes.
The move may signal China is accelerating the vaccine to hit the general market soon, but a false impression of the vaccine’s safety may be potentially misleading, says one regulatory expert.